Kathy Dietlin, MD
Allergy & Immunology · North Dartmouth, MANPI 1699734756
Payments from drug & device makers
Across 702 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$734
- Takeda Pharmaceuticals U.S.A., Inc.$687
- plus $5K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 185 | $4,244 |
| GSK | 92 | $1,663 |
| Sanofi | 43 | $1,097 |
| Regeneron Healthcare Solutions, Inc. | 43 | $1,043 |
| CSL Behring | 33 | $734 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $687 |
| Novartis | 44 | $626 |
| Genentech USA, Inc. | 49 | $524 |
| Boehringer Ingelheim | 21 | $445 |
| Pharming Healthcare, Inc. | 19 | $426 |
| Pfizer | 23 | $385 |
| Teva Pharmaceuticals USA, Inc. | 14 | $293 |
| Kaleo, Inc. | 17 | $283 |
| AbbVie | 11 | $272 |
| Biocryst US Sales Co., LLC | 10 | $217 |
| LEO Pharma Inc. | 7 | $177 |
| Aimmune Therapeutics, Inc. | 8 | $157 |
| Shire North American Group Inc | 12 | $141 |
| Amgen | 7 | $138 |
| Covis Pharma GmbH | 7 | $127 |
| Optinose US, Inc. | 5 | $105 |
| Octapharma USA, Inc. | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Alk-abello, Inc | 3 | $44 |
| Incyte Corporation | 2 | $43 |
| Mylan Pharmaceuticals Inc. | 2 | $35 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Merck | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
$14,134 in reported general payments places this provider in the 60th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in North Dartmouth
- S David MillerNorth Dartmouth$8.7M
- Alan KatzNorth Dartmouth$20K
- Wanda PhipatanakulBoston$3.2M
- Maria CastellsGardner$2.8M
- Rima RachidBoston$1.1M
- Duane WesemannBoston$1M
- Matthew GiannettiBoston$720K
- John LeeBoston$695K
- Aleena BanerjiBoston$586K
- Michael PistinerBoston$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.